ERBB2 and breast carcinoma: We used a T&M methodology to assess the time and resources associated with the preparation and administration of trastuzumab IV and SC in a subgroup of patients with early HER2-positive breast cancer who participated in the patient preference for subcutaneous (SC) vs. Intravenous (IV) HERceptin (PrefHer) study (NCT01401166) [11, 12] in three Spanish centers [10].